NCT00119457已完成2 期
A Multi-Center, Placebo-Controlled Evaluation of the Safety and Efficacy of Three Weeks Extended VTE Prophylaxis With Daily Oral Doses of TTP889 After One Week of Standard Prophylactic Treatment Following Hip Fracture Surgery
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 300
- 试验地点
- 41
- 主要终点
- To evaluate the antithrombotic efficacy of TTP889, administered once daily for three weeks, in patients who have completed standard prophylactic treatment for deep vein thrombosis after hip fracture surgery.
研究概览
简要总结
The purpose of this study is to determine whether TTP889 prevents venous thromboembolism following surgery to repair hip fracture.
详细描述
FIXIT is the first Phase 2 study of TTP889. The trial is a proof-of-concept study to determine the safety and antithrombotic efficacy of TTP889 in patients at risk for venous thromboembolism (VTE). The study is a multi-center, randomized, double-blind, parallel-group evaluation of 300 mg TTP889 or placebo, administered orally once daily for three weeks, in patients who have undergone surgery to repair unilateral fracture of the upper third of either femur and who have completed 5 to 9 days of postoperative prophylactic treatment for VTE.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must have undergone reparative surgery within 72 hours after unilateral hip fracture, defined as fracture of the upper third of either femur
- •Must have started standard prophylactic treatment for VTE with low molecular weight heparin (LMWH) or heparin before surgery or within 24 hours after hip fracture surgery, and continued treatment with LMWH or heparin for at least five days, but not more than nine days, after surgery
- •Last dose of LMWH or heparin must have been administered at least 12 hours, but not more than 48 hours, before dosing with study drug
- •Females must have a negative serum pregnancy test
- •Must weigh at least 45 kg
- •Must demonstrate the mental and physical ability and willingness to follow all study-specific instructions
- •Must be able to read, comprehend and sign the Ethics Committee-approved informed consent form
排除标准
- •Evidence of active bleeding
- •Clinical signs of VTE
- •Any medical requirement for (or intention to use) continued anticoagulation after randomization through the end of study
- •History of intracranial bleeding, hemorrhagic stroke, or gastrointestinal bleeding within 3 months of study start
- •Presence of active malignant disease
- •Hip fracture associated with multiple trauma, that places patient at excessive risk for hemorrhage or organ system failure, or that may make it difficult or impossible to perform bilateral lower limb venography
- •Intention to take aspirin at doses greater than 325 mg/day
- •Hemoglobin < 5.45 mmol/L (9 g/dL), hematocrit < 29%, or a platelet count < 100,000/mL at the screening visit
- •Elevated ALT or AST level > 3.0 times the ULN, or an elevated total bilirubin > 1.5 the ULN at the screening visit
- •Creatinine > 180 mmol/L (2.0 mg/dL) at the screening visit
- •Any other laboratory value at screening that the Investigator considers to be clinically significant and warrants exclusion from the study
- •Patient is currently breast feeding a child and wishes to continue breast feeding
- •Previous allergy to contrast material or any other contraindications to perform bilateral lower limb venography
- •The use of another investigational drug within 28 days of study entry
结局指标
主要结局
To evaluate the antithrombotic efficacy of TTP889, administered once daily for three weeks, in patients who have completed standard prophylactic treatment for deep vein thrombosis after hip fracture surgery.
Evaluation of safety of once daily oral administration of TTP889 for three weeks
次要结局
- To assess the correlation between peak and trough plasma concentrations of TTP889 and clinical safety and efficacy outcomes.
研究者
研究点 (41)
Loading locations...
相似试验
已完成
3 期
Prevention of Recurrent Venous Thromboembolism (PREVENT)Cardiovascular DiseasesHeart DiseasesPeripheral Vascular DiseasesThromboembolismVascular DiseasesVenous ThromboembolismNCT00000614National Heart, Lung, and Blood Institute (NHLBI)
已完成
不适用
A Clinical Cohort Study of Safety and Effectiveness of Venous Thromboembolism Prophylaxis in Critical Ill PatientsHemorrhageVenous ThromboembolismNCT02213978Beijing Chao Yang Hospital1,114
已完成
不适用
Intermittent Pneumatic Compression in Surgical Patients at Extremely-high Risk for Venous ThromboembolismVenous ThromboembolismVenous ThrombosisNCT03044574Pirogov Russian National Research Medical University407
招募中
不适用
5E Program for Preventing Venous Thromboembolism in Patients With Spinal Cord DisordersSpinal Cord DiseasesSpinal Cord InjuriesNurse's RoleVenous ThromboembolismNCT06302478Khon Kaen University42
已完成
不适用
Multicenter retrospective study of thrombolytic therapy including AT-III for portal vein thrombosisportal vein thrombusJPRN-UMIN000044249Department of Gastroenterology, Nippon Medecial School240